New eye implant aims to stop vision loss from diabetes
NCT ID NCT06003751
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tested a new eye implant called PER-001 in 27 people with diabetic retinopathy, a diabetes complication that can damage vision. The implant is placed inside the eye and releases medication over time. The main goal was to check safety and how well people tolerate it, looking at vision changes and eye pressure. The trial is now complete, but results are not yet available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PER-001 intravitreal implant
What this could lead to
If successful, this could lead to a new treatment option for diabetic retinopathy that helps preserve vision.
What could go wrong
This is a small, early-phase trial focused on safety, not effectiveness. The implant may not improve vision or could cause side effects like eye pressure changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC RETINOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Perfuse Therapeutics, Inc
San Francisco, California, 94158, United States